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Abstract. Prothrombin is determined with the aid of a recently developed assay, based
on the amidolysis of a chromogenic substrate. The assay proved to be reliable when it was
compared with more conventional coagulation assays in the control of oral anticoagulant
therapy, both in the therapeutic range and in a case of overdosage. As is the case in
coagulation tests, heparin thelapy remains a disturbing circumstance. The prothrombin
concentration was measuted (a) in the plasma of 50 long-term anticoagulated patients, and
the results were compared with those obtained with a one-stage coagulation assay and with
those obtained with Thrombotest@ determinations, and (b) during vitamin K administration
in the plasma of a patient with a severe intoxication of a vitamin K antagonist.
I ntroduction
Recently, we developed a method for the determination of prothrombin
with the use of a chromogenic substrate (5). In this method, prothrombin is first
activated with human factor Xu and, in a second stage, the thrombin concentra'
tion is determined by its amidolytic activity towards a synthetic substrate
(Chromozym@ TH). From this substrate, thrombin liberates the yellow-coloured
p-nitroanilide. The thrombin concentration is proportional to the generation rate
of p-nitroanilide which can be recorded spectrophotometrically and is expressed
as absorbancy change per unit of time. Here we present results conceming the
practical value of this assay for routine prothrombin determination.
t With support from the'Deutsche Forschungsgemeinschaft'.
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Materials and Methods
Buffers. Buffer A: 0.075M NaCl, 0.075 M imidazol, 0.075M tris-HCl, pH8.4.
BufferB: 0.087 }f NaCl,0.0029Msodiumacetate,0.0029M sodiumbarbital,pHT.4.
Reagents. Thrombotest@ was obtained from Nyegaard (Norway). Heparin, 5,000 U/ml,
from Organon (The Netherlands), Chromozym TH from Boehringer, Mannheim (FRG) and
Taipan snake venom from Sigma (USA).
Plasma and Coagulation Factors. Plasma was prepared by collecting blood in 0.13M
trisodium citrate (I0% v/v) and separated from the cells by centrifuging for 10 min at
2,000g. Factor X" was prepared as described before (5), and bovine thrombin was obtained
as Topostasine@ from Roche (Switzerland) dissolved in buffer B to a concentration of
50 NIH U/ml and stored at -20 "C. Antiprothrombin was prepared as described by Bas et
al. (2).
Prothrombin Determination (1) One-stage coagulation assay as described by Koller et
a/. (6), modified in such a way that only human material was used. (2) Two-stage method
with the aid of Chromozym TH as described earlier (5). (3) One-dimensional electrophoresis
according ts Laurell (8).
Results
Determination of hothrombin in Anticoagulated Patients
Plasma was obtained from 50 patients randomly chosen from the local
thrombosis service, and the prothrombin concentration was measured with the
one-stage coagulation assay and the chromogenic substrate assay. The relation
between the values obtained in these tests is shown in figure 1. The level of
significance (p) of the correlation between these methods was 0.05 (t test). With
the routinely used Thrombotest, a positive correlation of 0.69 was found in the
range 5-15 of the Spearman rank correlation coefficient. The determination of
prothrombin in a case of vitamin K antagonist intoxication presents a test case
to exclude the possibility that decarboxyprothrombin (Pivka-II) is coestimated
in our tests.
In the case at hand, the Thrombotest and the concentration of pro
tlrombin, factor VII and factor X (all measured with the one-stage coagulation
assay) were below 5% of the normal values. The increase of the prothrombin
level after a single oral dose of 30 mg vitamin K was assayed with the method
using chromogenic substrates. The results are shown in figure 2. The results were
similar to those obtained with the one-stage coagulation assay. Immediately after
administration of vitamin K, a sharp increase of the prothrombin concentration
was observed, which leveled off after 2 more days.
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Fig. 2. Time course of the prothrombin generation in plasma after vitamin K antagonist
intoxication. Blood was collected at the first 6 days ofhospitalization. The 2nd day, 30 mg
of vitamin K were given orally, immediately after collecting the blood. Prothrombin was
assayed either with a onestage method (o) or with the aid of a chromogenic substrate. In
the latter case, prothrombin was activated either with factor X" (o) or with Taipan snake
venom (o) or with staphylocoagulase (*).
antigenic determinants. No significant differences were observed between these
results and those shown in figure 2.
In current practice, heparin therapy interferes with the results of coagula-
tion factor determination. This is also the case with this method using chromo
genic substrates. Nevertheless, in the presence of small therapeutic amounts of
heparin in the plasma, small amounts of prothrombin will be determined
correctly (fig. 3).
Discussion
A recently developed method for the determination of protfuombin was
tested in 50 patients, who were on oral anticoagulation therapy. The correlation
between the new assay and the one-stage prothrombin assay was good. The
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Fig. 3. Increase of the prothrombin concentration in normal plasma as a function of
the plasma dilutions in the presence (r) or absence (x) of 0.25 U heparin/ml plasma. For
further details. see Materials and Methods.
correlation between the data obtained with the routinely used Thrombotest
assay and those obtained with specific prothrombin assays is moderate due to
the fact that the Thrombotest is a non-specific assay in which the clotting time is
dependent on the concentration of prothrombin as well as that of several other
coagulation factors.
Assays in which prothrombin is detected with the aid of a chromogenic
substrate have three advantages over the conventional coagulation assays: (a) the
assay can be easily adapted to automatic measurements; (b) the conformation of
fibrin as the end point of the reaction is avoided and hence the conditions
interfering with fibrin formation will not disturb the test (3), and (c) the
conditions of the test can be more strictly standardized than those of a
coagulation test.
As can be seen from the experiments in which the new prothrombin assay
was used to register the prothrombin concentration in the plasma of a patient
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with a severe vitirmin K antagonist intoxication, only normal prothrombin was
measured when factor Xu was used as a prothrombin activator. On the other
hand, the sum of the concentrations of prothrombin and decarboxyprothrombin
(PivkaJI) was measured when staphylocoagulase or Taipan snake venom was
used as prothrombin activator.
Axelsson et al. (l) and Korsan-Bengtsen et al. (7) have used a similar assay
system to control anticoagulant therapy. However, because these authors
used different prothrombin activators than we did, their methods had some
imperfections. Axelsson et aL used a commercial tissue thromboplastin which
had the disadvantage that different thromboplastin concentrations were required
at different prothrombin concentrations, even when these concentrations were
in the normal range for anticoagulant therapy. Moreover, a rather high con-
centration of factor V elWo) was required for a maximal reaction rate. Korsan-
Bengtsen et aL used Russell's viper venom as an indirect prothrombin activator.
These authors found that the factors II, V, VII and X were activated in this
system and that the rate of activation of each one of these factors differed.
These activation rates differed from each other and were dependent on the
incubation time and on the venom concentration. The system became even more
complicated when prothrombin was measured during anticoagulant therapy,
because also the decarboxyfactors II, VII and X are slowly activated and hence
decarboxyfactor II is partially coestimated.
With the modified method which we used in our investigations, these types
of shortcomings could be avoided because (a) decarboxyfactor II is not co-
estimated, (b) the reaction occurs in the absence of thromboplastin, (c) only l%
of factor V is required and (d) the only prothrombin activator is factor I which
is added to the samples in excess.
As the occurrence of decarboxyprothrombin is pathogenic for vitamin K
deficiency (4), this test allows to diagnose a vitamin K deficiency instantaneous-
ly. This may be of importance, not only to spot an intoxication quickly, but also
to recognise the contribution of vitamin K deficiency due to resorption defects
in the low coagulation factor level found in liver disease.
From the experiments presented in this paper, we conclude that the new
prothrombin assay correlates very well with the specific coagulation assays in
varying types of experiments. As it is a quick and easy assay, it is fit for the
routine determination of prothrombin in the plasma of anticoagulated patients
and may be adapted to automatic measurements in the laboratories of clinical
chemistry. It can be easily modified to a test that immediately indicates whether
or not a patient has a vitamin K deficiency.
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